TW202128771A - 抗trem2 抗體及其使用方法 - Google Patents

抗trem2 抗體及其使用方法 Download PDF

Info

Publication number
TW202128771A
TW202128771A TW110101213A TW110101213A TW202128771A TW 202128771 A TW202128771 A TW 202128771A TW 110101213 A TW110101213 A TW 110101213A TW 110101213 A TW110101213 A TW 110101213A TW 202128771 A TW202128771 A TW 202128771A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
amino acid
acid sequence
sequence
Prior art date
Application number
TW110101213A
Other languages
English (en)
Chinese (zh)
Inventor
馬克 S 丹尼斯
振宇 顧
米漢利斯 卡里歐立斯
凱瑟 馬翁
凱瑟琳 Ｍ 夢露
約書亞 Ｉ 朴
瑞秋 普洛洛可
亞當 P 席佛曼
倫格里希 貝汀娜 凡
Original Assignee
美商戴納立製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戴納立製藥公司 filed Critical 美商戴納立製藥公司
Publication of TW202128771A publication Critical patent/TW202128771A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110101213A 2020-01-13 2021-01-13 抗trem2 抗體及其使用方法 TW202128771A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US62/960,663 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US63/070,728 2020-08-26
US202063091717P 2020-10-14 2020-10-14
US63/091,717 2020-10-14

Publications (1)

Publication Number Publication Date
TW202128771A true TW202128771A (zh) 2021-08-01

Family

ID=74587108

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110101213A TW202128771A (zh) 2020-01-13 2021-01-13 抗trem2 抗體及其使用方法

Country Status (4)

Country Link
CL (1) CL2022001886A1 (fr)
EC (1) ECSP22054464A (fr)
TW (1) TW202128771A (fr)
WO (1) WO2021146256A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법
WO2023164516A1 (fr) 2022-02-23 2023-08-31 Alector Llc Méthodes d'utilisation d'anticorps anti-trem2
WO2023192288A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation
WO2023192282A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Méthodes de traitement de l'hypométabolisme du glucose cérébral

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
CA2997960A1 (fr) * 2015-10-06 2017-04-13 Alector Llc Anticorps anti-trem2 et leurs procedes d'utilisation
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019028292A1 (fr) 2017-08-03 2019-02-07 Alector Llc Anticorps anti-trem2 et leurs procédés d'utilisation
JP7403441B2 (ja) * 2017-09-14 2023-12-22 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法

Also Published As

Publication number Publication date
WO2021146256A1 (fr) 2021-07-22
CL2022001886A1 (es) 2023-03-24
ECSP22054464A (es) 2022-08-31

Similar Documents

Publication Publication Date Title
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
JP7403441B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7107836B2 (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用
JP6931609B2 (ja) 抗Ａｘｌアンタゴニスト抗体
TW202128771A (zh) 抗trem2 抗體及其使用方法
KR20190134997A (ko) 항-tau 항체 및 이의 사용 방법
US20220119522A1 (en) Anti-trem2 antibodies and methods of use thereof
JP2023123757A (ja) トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
KR102345173B1 (ko) 증가된 안정성을 가진 인간화 항체
TW202003570A (zh) 抗trem-1抗體及其用途
TW201522373A (zh) 抗ｃｄ５２之抗體
CN113614107A (zh) Cd31竞争剂及其用途
JP2022502040A (ja) アンタゴニスト
WO2023192288A1 (fr) Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation
TW202337906A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
CN117586390A (zh) 抗cgrp抗体及用途